This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zee, R. Y. L. Articles by Fernandez-Cruz, A. Search for Related Content PubMed PubMed Citation Articles by Zee, R. Y. L. Articles by Fernandez-Cruz, A. Related Collections Restenosis Genetics of cardiovascular disease

(Hypertension. 2001;37:851.)
© 2001 American Heart Association, Inc.

Scientific Contributions

ACE D/I Polymorphism and Incidence of Post-PTCA Restenosis

A Prospective, Angiography-Based Evaluation

Robert Y. L. Zee; Antonio Fernandez-Ortiz; Carlos Macaya; Emilio Pintor; Klaus Lindpaintner; Arturo Fernandez-Cruz

From the Endocrine-Hypertension Division (R.Y.L.Z., K.L.), Department of Medicine, Brigham and Women’s Hospital, and the Department of Cardiology (K.L.), Children’s Hospital, Harvard Medical School, Boston, Mass; Hospital Universitario San Carlos (A.F-Z., C.M., E.P., A.F-Z.), Ciudad Universitaria, Madrid, Spain; and the Max Delbruck Centre for Molecular Medicine (K.L.), Berlin, Germany.

Correspondence to Robert Y.L. Zee, PhD, Endocrine-Hypertension Division, Room 209, Longwood Medical Research Center, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA, 02115. E-mail rylz{at}calvin.bwh.harvard.edu

Early restenosis is the major complication of percutaneous transluminal coronary angioplasty (PTCA), occurring in 30% of all initially successful procedures. The D/I polymorphism of the ACE gene, which has variably been reported to represent a risk factor for manifestations of ischemic heart disease, has recently been implicated in the pathophysiology of restenosis after PTCA by some investigators but not by others. All studies conducted thus far involved relatively small sample sizes. We investigated the possible association of ACE D/I genotype and post-PTCA restenosis in a large, prospective sample of patients followed by quantitative coronary angiography. The ACE D/I gene polymorphism was characterized in a cohort of 779 patients, of whom 342 (cases) had developed restenosis (as defined by >50% loss of lumen compared with immediate postprocedure results) at repeat quantitative coronary angiography at 6 months after PTCA. Allele frequencies for the ACE D and I alleles were 0.58 and 0.42 in cases and 0.58 and 0.42 in control subjects. All observed genotype frequencies were in Hardy-Weinberg equilibrium. There was no evidence for an association between genotype and restenosis or degree of lumen loss. The data from this largest study of its kind conducted so far provide no evidence for an association of the ACE D/I allelic polymorphism with incidence of restenosis after PTCA. On the basis of the power of this study, we conclude that in a general population, the ACE D/I polymorphism is not a useful marker to assess risk of post-PTCA restenosis.

Key Words: angiotensin-converting enzyme • angioplasty • polymorphism • genetics • risk factors

This article has been cited by other articles:

				M Hamon, S Fradin, A Denizet, E Filippi-Codaccioni, G Grollier, and R Morello Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention Heart, March 1, 2003; 89(3): 321 - 325. [Abstract] [Full Text] [PDF]

				F. Bonnici, B. Keavney, R. Collins, and J. Danesh Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies BMJ, September 7, 2002; 325(7363): 517 - 520. [Abstract] [Full Text] [PDF]